Akebia Therapeutics (AKBA) Expected to Announce Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) is expected to be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $44.88 million for the quarter.

Akebia Therapeutics (NASDAQ:AKBA) last issued its earnings results on Thursday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.05). The firm had revenue of $46.50 million for the quarter, compared to analyst estimates of $37.36 million. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Akebia Therapeutics Trading Down 0.8 %

AKBA stock opened at $2.41 on Thursday. The firm has a market cap of $569.32 million, a P/E ratio of -10.48 and a beta of 0.87. Akebia Therapeutics has a 1-year low of $0.80 and a 1-year high of $2.89. The business’s 50 day moving average is $1.98 and its 200-day moving average is $1.94.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. StockNews.com downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, April 25th. Jefferies Financial Group assumed coverage on Akebia Therapeutics in a research note on Tuesday, April 1st. They issued a “buy” rating and a $6.00 target price for the company. Piper Sandler increased their price objective on shares of Akebia Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, March 14th. Leerink Partnrs upgraded Akebia Therapeutics to a “strong-buy” rating in a research report on Monday. Finally, Leerink Partners began coverage on Akebia Therapeutics in a research note on Monday. They set an “outperform” rating and a $7.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.63.

Insider Buying and Selling

In other Akebia Therapeutics news, CAO Richard C. Malabre sold 30,202 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $63,424.20. Following the transaction, the chief accounting officer now owns 280,248 shares of the company’s stock, valued at $588,520.80. The trade was a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Steven Keith Burke sold 50,506 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total value of $106,062.60. Following the transaction, the senior vice president now directly owns 816,234 shares in the company, valued at $1,714,091.40. The trade was a 5.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 280,579 shares of company stock worth $589,216. 4.10% of the stock is owned by insiders.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.